ClinicalTrials.gg
CompletedNCT01737931Updated Apr 29, 2014Results posted

A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject

A Phase 1 interventional study of Topical steroid (Dexamethasone) and Topical antihistamine (Diphenhydramine) in Healthy, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 2 sites in Korea, Republic of. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-29.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Study summary

To investigate the efficacy of symptomatic therapy with topical steroids and antihistamines for application site reaction (ASR) after administration of SPM 962 in healthy subjects

02

Conditions studied

  • Healthy

Keywords

  • SPM 962
  • rotigotine
  • application site reaction
03

In context

Lead sponsor

Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a male or female and aged between 20 and 45 years of age (inclusive)
  • Subject is of normal body weight as determined by a body-mass index () between 18 and 28 kg/m2
  • Subject is healthy as determined by EA (medical history, physical examination, skin evaluation, vital signs, , hematology, clinical chemistry, urinalysis)
  • Subject is surgically sterile; subject has been for at least 12 consecutive months if female; or subject agrees to remain abstinent or to follow two acceptable methods of from EA to the end of observation period. (fore male and female subjects)

Exclusion criteria

Exclusion Criteria:

  • Subject has a history or complication of epilepsy and/or seizures
  • Subject has changes in the , such as second- or third-degree AV block, a complete bundle branch block, prolongation of the QRS complex over 120 ms, or of the (QT interval corrected for HR by Bazett´s formula) over 500 ms at EA
  • Subject has a clinically relevant hepatic dysfunction
  • Subject has a clinically relevant renal dysfunction
  • Subject has a history of significant skin to adhesives or other transdermal products or recent unresolved contact dermatitis
  • Subject has a history or complication of atopic or eczematous dermatitis, psoriasis, and/or an active skin disease or skin tumors
  • Subject has more than 1 known or suspected drug hypersensitivity, in particular to any component of the trial medication
  • Subject has a history of chronic alcohol or drug abuse within the last 5 years
  • Subject is tested positive for -1/2Ab, or -Ab
  • Subject tests positive for alcohol and/or drugs at EA
  • Subject is taking any prohibited concomitant medication
  • Subject has a history or complication of narrow angle glaucoma
  • Subject has a history or complication of respiratory or cardiovascular disorders (e.g., heart failure, coronary heart disease, hypertension, arrhythmia, tachyarrhythmia, or myocardial infarction)
  • Subject has a history or complication of psychic abnormality, psychiatric or neurologic illness, or autonomic neuropathy
  • Subject has a history or complication of diabetes mellitus and/or thyroid dysfunction, especially hyperthyroidism or other endocrine disorders
  • Subject has a history or complication of
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Topical Steroid

    Topical medication of steroid (Dexamethasone) to the application sites after the patch removal

    Drug: Topical steroid (Dexamethasone)

  • Experimental
    Topical antihistamine

    Topical medication of antihistamine(Diphenhydramine) to the application sites after the patch removal

    Drug: Topical antihistamine (Diphenhydramine)

  • No intervention
    No-treatment

    No treatment to the application sites after the patch removal

Interventions

  • for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal

  • for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal

06

What researchers measure

Primary outcomes

  1. Skin Irritation Score of the Application Site

    Skin irritation score of the application site 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.

    Time frame: 24 hours after 2 mg/24 hr patch removal

  2. Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)

    Itching of application site evaluated by the visual analogue scale (VAS) 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The score ranges from 0 (no itching) to 100 (strongest imaginable itching).

    Time frame: 24 hours after 2 mg/24 hr patch removal

Secondary outcomes

  1. Skin Irritation Score After Patch Removal

    Numbers of subjects with each skin irritation score. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.

    Time frame: Up to 72 hours after patch removal

  2. Itching of Application Site Evaluated by VAS After Patch Removal

    Changes of itching of application site evaluated by VAS after patch removal (acceleration and dose-escalation periods). The score ranges from 0 (no itching) to 100 (strongest imaginable itching).

    Time frame: Up to 96 hours after patch removal

07

Results

Posted Apr 29, 2014

Participant flow

Participant flow — Overall Study
MilestoneTopical SteroidTopical AntihistamineNo-treatment
Started384039
Completed383838
Not completed021
Withdrew: Withdrawal by subject011
Withdrew: Physician decision010

Outcome measures

PrimarySkin Irritation Score of the Application Site

Skin irritation score of the application site 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.

Time frame:
24 hours after 2 mg/24 hr patch removal
Reported as:
Mean · Scores on a scale
Skin Irritation Score of the Application Site
Scores on a scaleTopical SteroidTopical AntihistamineNo-treatment
Skin Irritation Score of the Application Site0.237 (0.084 to 0.390)0.289 (0.136 to 0.422)0.250 (0.101 to 0.399)
PrimaryItching of Application Site Evaluated by the Visual Analogue Scale (VAS)

Itching of application site evaluated by the visual analogue scale (VAS) 24 hours after 2 mg/24 hour patch removal (dose-escalation period) and difference between Steroid or Antihistamine and No-treatment. The score ranges from 0 (no itching) to 100 (strongest imaginable itching).

Time frame:
24 hours after 2 mg/24 hr patch removal
Reported as:
Mean · Scores on a scale
Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)
Scores on a scaleTopical SteroidTopical AntihistamineNo-treatment
Itching of Application Site Evaluated by the Visual Analogue Scale (VAS)1.6 (0.5 to 2.7)0.4 (-0.7 to 1.6)0.9 (-0.2 to 2.0)
SecondarySkin Irritation Score After Patch Removal

Numbers of subjects with each skin irritation score. The scale scoring criteria are 0(-): Negative, 0.5(±): Faint erythema, 1(+): Erythema, 2(++): Erythema + edema, 3(+++): Erythema + edema + papules, serous papule, vesicles, 4(++++): Coalescing vesicles.

Time frame:
Up to 72 hours after patch removal
Reported as:
Number · Percentage of participants
Skin Irritation Score After Patch Removal
Percentage of participantsTopical SteroidTopical AntihistamineNo-treatment
- (1 hour after patch removal)5.35.610.0
± (1 hour after patch removal)63.255.645.0
+ (1 hour after patch removal)31.638.945.0
- (24 hours after patch removal)57.952.660.0
± (24 hours after patch removal)36.836.830.0
+ (24 hours after patch removal)5.310.510.0
- (48 hours after patch removal)89.594.780.0
± (48 hours after patch removal)10.55.320.0
- (72 hours after patch removal)94.494.790.0
± (72 hours after patch removal)5.65.310.0
SecondaryItching of Application Site Evaluated by VAS After Patch Removal

Changes of itching of application site evaluated by VAS after patch removal (acceleration and dose-escalation periods). The score ranges from 0 (no itching) to 100 (strongest imaginable itching).

Time frame:
Up to 96 hours after patch removal
Reported as:
Mean · Scores on a scale
Itching of Application Site Evaluated by VAS After Patch Removal
Scores on a scaleTopical SteroidTopical AntihistamineNo-treatment
3 hours after patch removal-2.8 ± 6.9-3.0 ± 9.0-2.2 ± 4.6
6 hours after patch removal-3.3 ± 7.9-3.3 ± 8.6-2.3 ± 5.0
24 hours after patch removal-3.9 ± 10.0-2.6 ± 7.0-2.6 ± 4.7
48 hours after patch removal-3.9 ± 10.5-3.6 ± 9.0-2.9 ± 5.1
72 hours after patch removal-4.1 ± 10.0-3.8 ± 8.9-3.0 ± 5.1
96 hours after patch removal-4.3 ± 10.1-3.8 ± 8.9-3.0 ± 5.1

Adverse events

Collected over 7 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Over-all—0/120 (0%)41/120 (34.2%)
Most frequent other events
Most frequent other events
EventOver-all
ErythemaSkin and subcutaneous tissue disorders29/120
HeadacheNervous system disorders6/120
SomnolencePsychiatric disorders6/120
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders6/120
RhinorrhoeaRespiratory, thoracic and mediastinal disorders4/120
Application Site IrritationGeneral disorders3/120
Feeling HotGeneral disorders3/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)Topical SteroidTopical AntihistamineNo-treatmentTotal
Mean26.7 ± 4.226.7 ± 4.826.1 ± 3.726.5 ± 4.3
Age, Categorical
Age, Categorical(Participants)Topical SteroidTopical AntihistamineNo-treatmentTotal
<=18 years0000
Between 18 and 65 years384039117
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Topical SteroidTopical AntihistamineNo-treatmentTotal
Female0000
Male384039117
Region of Enrollment
Region of Enrollment(participants)Topical SteroidTopical AntihistamineNo-treatmentTotal
Korea, Republic of384039117
08

Study locations

2 sites
  • Seoul National University Bundang Hospital
    Kyeonggi-do, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Oct 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2012
First posted
Nov 30, 2012
Start
Aug 2012
Primary completionActual
Oct 2012
CompletionActual
Nov 2012
Results first posted
Apr 29, 2014
Last update
Apr 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01737931
Responsible party
Sponsor
First posted
Nov 30, 2012
Start date
Aug 2012
Primary completion
Oct 2012
Completion
Nov 2012
Results posted
Apr 29, 2014
Last update
Apr 29, 2014

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Steroids · Diphenhydramine

Start the discussion